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Tolerability of malaria chemoprophylaxis in non-immune
travellers to sub-Saharan Africa: multicentre, randomised,
double blind, four arm study
Patricia Schlagenhauf, Alois Tschopp, Richard Johnson, Hans D Nothdurft, Bernhard Beck,
Eli Schwartz, Markus Herold, Bjarne Krebs, Olivia Veit, Regina Allwinn, Robert Steffen
Abstract
Objective To compare the tolerability of malaria
chemoprophylaxis regimens in non-immune
travellers.
Design Randomised, double blind, study with placebo
run-in phase.
Setting Travel clinics in Switzerland, Germany, and
Israel.
Main outcome measure Proportion of participants in
each treatment arm with subjectively moderate or
severe adverse events.
Participants 623 non-immune travellers to
sub-Saharan Africa: 153 each received either
doxycycline, mefloquine, or the fixed combination
chloroquine and proguanil, and 164 received the
fixed combination atovaquone and proguanil.
Results A high proportion of patients reported
adverse events, even in the initial placebo group. No
events were serious. The chloroquine and proguanil
arm had the highest proportion of mild to moderate
adverse events (69/153; 45%, 95% confidence interval
37% to 53%), followed by mefloquine (64/153; 42%,
34% to 50%), doxycycline (51/153; 33%, 26% to 41%),
and atovaquone and proguanil (53/164; 32%, 25% to
40%) (P = 0.048 for all). The mefloquine and
combined chloroquine and proguanil arms had the
highest proportion of more severe events (n = 19;
12%, 7% to 18% and n = 16; 11%, 6% to 15%,
respectively), whereas the combined atovaquone and
proguanil and doxycycline arms had the lowest
(n = 11; 7%, 2% to 11% and n = 9; 6%, 2% to 10%,
respectively: P = 0.137 for all). The mefloquine arm
had the highest proportion of moderate to severe
neuropsychological adverse events, particularly in
women (n = 56; 37%, 29% to 44% versus chloroquine
and proguanil, n = 46; 30%, 23% to 37%; doxycycline,
n = 36; 24%, 17% to 30%; and atovaquone and
proguanil, n = 32; 20%, 13% to 26%: P = 0.003 for all).
The highest proportion of moderate or severe skin
problems were reported in the chloroquine and
proguanil arm (n = 12; 8%, 4% to 13% versus
doxycycline, n = 5; 3%, 1% to 6%; atovaquone and
proguanil, n = 4; 2%, 0% to 5%; mefloquine, n = 2; 1%,
0% to 3%: P = 0.013).
Conclusions Combined atovaquone and proguanil
and doxycyline are well tolerated antimalarial drugs.
Broader experience with both agents is needed to
accumulate reports of rare adverse events.
Introduction
Each year an estimated 50 million travellers visit
malaria endemic areas. Around 30 000 cases of
malaria are reported annually in non-endemic,
industrialised countries, and this imported malaria
remains a public health problem with its high
mortality.1 Recommendations vary widely as to the
optimum prophylactic treatments for travellers to high
risk endemic areas, such as sub-Saharan Africa. Four
regimens are currently available: mefloquine, com-
bined atovaquone and proguanil, doxycycline, and
combined chloroquine and proguanil.2–5 The lack of
unanimity about which regimen to prescribe is mainly
due to controversy about the tolerability of antimalar-
ial drugs in non-immune, healthy travellers and a pau-
city of data from randomised controlled studies.
Two double blind studies found that tolerability to
combined atovaquone and proguanil was better than
to mefloquine or combined chloroquine and pro-
guanil.6 7 We compared the tolerability of non-immune
travellers to the four commonly recommended
antimalarial regimens.
Participants and methods
Between 1998 and 2001, we recruited people seeking
advice before travelling to malaria endemic areas.
Inclusion criteria were a consultation at least 17 days
before departure, written informed consent, age
between 18 and 70 years, and planned travel for 1-3
weeks in sub-Saharan Africa (mainly Kenya and game
parks in the Republic of South Africa). Exclusion crite-
ria were known deficiency for glucose-6-phosphate
dehydrogenase, a history of severe adverse events with
any of the four study drugs or a contraindication for
their use, pregnancy or unwillingness to adhere to reli-
able contraception, history of seizures, psychiatric
disorders, severely impaired renal or hepatic function,
concurrent or recent vaginal infections or bacterial
enteric disorder, a history of photosensitivity, or
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unwillingness to adhere to the study protocol. Our
study was not powered to evaluate the efficacy of the
regimens for malaria prevention. No cases of malaria
were reported for any study arm.
Assignment to regimen and masking
Participants received drugs daily for 17 days before
departure, during the stay in Africa, and for four weeks
after return (see fig 1). The treatment groups were
assigned the following regimens: group 1, doxycycline
monohydrate 100 mg once daily (Vibramycin; Pfizer);
group 2, combined chloroquine diphosphate 161.21
mg (equivalent to chloroquine 100 mg base) and pro-
guanil hydrochloride 200 mg once daily (Savarine;
Zeneca); group 3, mefloquine hydrochloride 274.09
mg (equivalent to 250 mg mefloquine base; Lariam;
Roche) once weekly for 17 days before departure, dur-
ing the stay in Africa, and for four weeks after return
(placebo capsules were taken on the six days when no
active drug was required); and group 4, combined
atovaquone 250 mg and proguanil hydrochloride 100
mg (Malarone; GlaxoSmithKline) once daily for 17
days before departure, during the stay in Africa, and for
one week after return, then placebo daily for three
weeks.
A placebo run-in phase for one quarter of
participants in each arm was incorporated into the
first week of study intake. These participants then
joined one of the active treatment groups according to
randomisation.
The drugs were provided as identical capsules blis-
ter packed in weekly cards. Randomisation was
performed by the company that packed the study
drugs (Quintiles; West Lothian, Scotland). Random-
isation was from a computer generated table of
numbers in permuted blocks of five. Participants were
allocated treatment sequentially in order of study
numbers. Allocation concealment was by sealed
envelope.
Test instruments
Tolerability was assessed with three questionnaires.
Participants completed these during recruitment and
at follow up 13-11 days before departure, 6-4 days
before departure, and 7-14 days after return.
Adverse events
Adverse events were recorded using a questionnaire
similar to that used in a postal questionnaire survey of
UK travellers.8 We modified the questionnaire to
capture recognised, possible adverse events associated
with any of the four study drugs: nausea, diarrhoea,
mouth ulcers, itching, headache, strange or vivid
dreams, dizziness, anxiety, depression, visual distur-
bance, fits or seizures, abnormal reddening of the skin,
abnormal vaginal discharge or vaginal itching, and a
category for “any other.” Participants were asked to
grade the severity of the adverse events on a scale of 1
to 4: grade 1, trivial; grade 2, some interference with
daily activities; grade 3, medical advice sought; and
grade 4, hospital admission required.
Moods and feelings
Moods and feelings were captured by the profile of
mood states questionnaire.9 This questionnaire detects
tension, depression, anger, vigour, fatigue, and
confusion. Items were scored on a 5 point scale from 0
“not at all” to 4 “extremely.” The questionnaire has
been successfully used in studies on the tolerability of
malaria chemoprophylaxis in tourist and military
populations.10 11
Quality of life
Participants were asked to grade the 13 positive
statements, such as I can enjoy my everyday life, in the
quality of life questionnaire on a scale of 1 “not at all
true” to 6 “true,” The higher the score, the better the
perceived quality of life.
Statistical analyses
The main outcome measure was the proportion of
participants in each arm with subjectively moderate or
severe adverse events. The initial sample size was
intended to be 383 per arm, but because recruitment
was slower and more difficult than expected and there
was the possibility of the drugs exceeding their expiry
date, the study was closed before this sample size was
achieved.
Secondary outcome measures were the scores from
the profile of mood states and quality of life question-
naires. The 2 test was used to detect differences in the
rates and severity of self reported adverse events. We
also grouped adverse events in each arm by type
(neuropsychological, gastrointestinal, dermatological).
We performed logistic regression analyses to check for
any effect of sex or age on the incidence of adverse
events. SPSS version 6 was used for the statistical
analysis.
Analyses of variance were run on the scores for
mood states obtained for each group at each follow up.
The mean scores were converted to T scores to enable
comparison with published normal scores for college
students. To assess total mood disturbance, we summed
the scores across all six moods and weighed vigour
negatively. We checked differences in scores between
groups with repeated measures of analysis of variance,
and further analyses were checked for the effect of sex,
age, and follow up time on mood.
Quality of life scores were computed for each arm
for 13-11 days before departure to 7-14 days after
return. The mean score was used as an index score for
each arm. The score for the placebo run-in phase was
based on the results at recruitment and 13-11 days
before departure only.
Visit 1
Mefloquine
Doxycycline
Chloroquine with
proguanil
 Atovaquone with
proguanil
Study arm
Placebo
Run-in
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travel
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Fig 1 Study design
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Results
A total of 674 people (49% female) were recruited and
completed the adverse events’ questionnaire at
baseline (fig 2). After exclusion of drop-outs (changes
in travel plans, cancelled trips, decision not to take
part), our sample population comprised 623 people
who had reported any or no adverse event at baseline
or at follow up. Overall, 153 participants were assigned
to either mefloquine, doxycycline, or combined
cholorquine and proguanil, and 164 were assigned to
combined atovaquone and proguanil. Sex and age
profiles were similar in the arms. Analysis of mood was
performed on the 547 participants who completed the
mood states questionnaire at baseline and follow up.
Adverse events were analysed in 623 participants
who completed questionnaires at recruitment and at
least one of the follow up periods (table 1). Although a
high proportion of participants reported adverse
events, none were serious. At the first control time
point (13-11 days before departure) some adverse
event was reported by 34 (22%) participants in the
mefloquine arm, 36 (24%) in the chloroquine and pro-
guanil arm, 25 (16%) in the doxycycline arm, 25 (15%)
in the atovaquone and proguanil arm, and 24 (16%)
placebo users.
Twenty two participants withdrew from the study
owing to adverse events or because allocation conceal-
ment had had to be broken. Withdrawal was lowest in
the combined atovaquone and proguanil arm (n = 3;
2% (95% confidence interval, 0% to 4%), intermediate
in the doxycycline arm (n = 5; 3%, 0% to 6%) and
mefloquine arm (n = 6; 4%, 1% to 8%), and highest in
the combined chloroquine and proguanil arm (n = 8;
5%, 2% to 9%: P = 0.425). The grade of adverse event
leading to withdrawal was mild in five participants,
moderate in eight, and severe in five. No severity
grades were available for three withdrawals. No statisti-
cally significant difference was found in withdrawals
between the treatment arms (table 1).
Overall, 528 participants (85% of the sample popu-
lation) reported at least one adverse event of any sever-
ity, and 237 (38%) reported moderate to severe adverse
Eligible participants (n=674)
Randomisation
Atovaquone and
proguanil group (n=173)
Doxycycline
group (n=169)
Chloroquine and
proguanil group (n=166)
Did not travel (n=4)
Consent withdrawn (n=3)
Other:
  Participated in another
   study (n=1)
  Used concomitant
   antimalarial drug (n=1)
  Poor health (n=1)
Mefloquine
group (n=166)
Received study drug (n=166)
Were evaluated (n=164)
Used medication incorrectly (n=2)
Received study drug (n=156)
Were evaluated (n=153)
Did not travel (n=2)
Lost to follow up (n=1)
Received study drug (n=156)
Were evaluated (n=153)
Did not travel (n=3)
Received study drug (n=156)
Were evaluated (n=153)
Did not travel (n=2)
Lost to follow up (n=1)
Completed all evaluations (n=154)Completed all evaluations (n=142)Completed all evaluations (n=135)Completed all evaluations (n=138)
Did not travel (n=2)
Consent withdrawn (n=5)
Used concomitant
 antimalarial drug (n=1)
Lost to follow up (n=2)
Did not travel (n=4)
Consent withdrawn (n=6)
Lost to follow up (n=3)
Did not travel (n=1)
Consent withdrawn (n=3)
Lost to follow up (n=3)
Withdrawals due to
 adverse events (n=6)
Did not complete all
 evaluations (n=5)
Stopped dosing early (n=2)
Unknown (n=2)
Withdrawals due to
 adverse events (n=8)
Did not complete all
 evaluations (n=9)
Unknown (n=1)
Withdrawals due to
 adverse events (n=5)
Did not complete all
 evaluations (n=5)
Unknown (n=1)
Withdrawals due to
 adverse events (n=3)
Did not complete all
 evaluations (n=5)
Stopped dosing early (n=1)
Unknown (n=1)
Fig 2 Flow of participants through trial
Table 1 Incidence of adverse events in antimalarial prophylaxis arms according to severity. Values are numbers (percentages, 95%
confidence intervals) unless stated otherwise
Type of adverse event
Mefloquine group*
(n=153)
Chloroquine and proguanil
group (n=153) Doxycycline group (n=153)
Atovaquone and proguanil
(n=164) P value
Severity of adverse event:
Mild† 135 (88, 83 to 93) 131 (86, 80 to 91) 128 (84, 78 to 90) 134 (82, 75 to 88) 0.42
Moderate‡ 64 (42, 34 to 50) 69 (45, 37 to 53) 51 (33, 26 to 41) 53 (32, 25 to 40) 0.048
Severe§ 16 (11, 6 to 15) 19 (12, 7 to 18) 9 (6, 2 to 10) 11 (7, 2 to 11) 0.14
Withdrawals 6 (4, 1 to 8) 8 (5, 2 to 9) 5 (3, 0 to 6) 3 (2, 0 to 4) 0.42
*One participant had a transient ischaemic attack outside follow up; history of two episodes was not declared (mefloquine serum concentrations were negligible).
†Trivial but some discomfort noted.
‡Interferes with daily activity.
§Medical advice required.
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events (primary end point). The highest incidence was
in the combined chloroquine and proguanil arm and
the lowest in the combined atovaquone and proguanil
arm (n = 69; 45%, 37% to 53% and n = 53; 32%, 25% to
40%, respectively). Fifty five participants (9%) reported
at least one severe adverse event. The highest incidence
was in the combined chloroquine and proguanil arm
and the lowest in the doxycycline arm (n = 19; 12%, 7%
to 18% and n = 9; 6%, 2% to 10%) (table 1).
The mefloquine arm had the highest incidence of
moderate to severe neuropsychological events (n = 56;
37%, 29% to 44%: P = 0.003, table 2) and the lowest
incidence of moderate to severe skin events (n = 2; 1%,
0% to 3%: P = 0.013). The combined chloroquine and
proguanil arm had the highest incidence of moderate
to severe skin adverse events (n = 12; 8%, 4% to 12%).
Women reported significantly more neuropsychologi-
cal, gastrointestinal, and skin problems than men. Men
in the combined chloroquine and proguanil arm were
more likely to have moderate skin problems.Women in
the mefloquine arm were significantly more likely to
have moderate neuropsychological problems than
women in the doxycycline or combined atovaquone
and proguanil.
No significant differences in mood were found
between the treatment arms. Scores were in the normal
range, and means deviated by no more than one
standard deviation. All arms showed good mean index
scores for quality of life: combined atovaquone and
proguanil 4.9 (4.8 to 5.1); combined cholorquine and
proguanil 4.9 (4.6 to 5.0); doxycycline 4.8 (4.7 to 5.0);
and mefloquine 4.8 (4.7 to 4.9: P = 0.41 for all). The
mean index for the placebo group was 4.9.
Discussion
Tolerability to the four currently recommended
antimalarial drugs, mefloquine, doxycycline, combined
chloroquine and proguanil, and combined atovaquone
and proguanil, is high, with no serious adverse events
and good quality of life reported. Moods and feelings
were also good, with high scores for “vigour” and low
scores for “tension,” “depression,” “anger,” “fatigue,”
and “confusion”—the so-called iceberg profile.
Although several factors influence the choice of
antimalarial regimen, tolerability is important to
encourage compliance to treatment of non-immune
travellers to endemic areas. A recent evaluation of
circumsporozoite seroconversion studies showed
that a high proportion of travellers to West Africa,
East Africa, and South Africa will be exposed to
Plasmodium falciparum.12
Our study is the first to concomitantly examine the
tolerability of the currently recommended antimalarial
regimens in a uniform group of non-immune tourists.
Over three quarters of our participants reported inter-
current events. Even in the initial placebo group, where
travel was a not a confounding feature, the incidence of
adverse events was comparable to the active treatment
groups.
Relation to other studies
More that 3000 people have been enrolled in five
placebo controlled trials comparing combined
atovaquone and proguanil with either combined chlo-
roquine and proguanil, mefloquine, doxycycline, or
placebo alone. Our study agreed with the favourable
safety profile for atovaquone and proguanil shown in
comparator studies.6 7–13 Data on long term tolerability
and post marketing surveillance are now required.
Previous studies of doxycycline have been limited
to predominantly male soldiers in whom the drug was
well tolerated.14–21 Oesophageal ulceration associated
with doxycycline prophylaxis was a common reason
for admission to hospital of US troops deployed in
Somalia.22 This was not a problem in our study,
Table 2 Proportion of participants in each antimalarial prophylaxis arm reporting adverse events, by type and severity, Values are
numbers (percentages, 95% confidence intervals) unless stated otherwise
Type of adverse event Mefloquine group (n=153)
Chloroquine and proguanil
group (n=153) Doxycycline group (n=153)
Atovaquone and proguanil
group (n=164) P value
Neuropsychological*:
Severe 8 (5, 2 to 9) 6 (4, 1 to 7) 1 (1, 0 to 2) 5 (3, 0 to 6) 0.139
Moderate 56 (37, 29 to 44) 46 (30, 23 to 37) 36 (24, 17 to 30) 32 (20, 13 to 26) 0.003
All events 118 (77, 70 to 84) 107 (70, 63 to 77) 105 (69, 61 to 76) 109 (67, 60 to 74) 0.187
Gastrointestinal†:
Severe 6 (4, 1 to 7) 9 (6, 2 to 10) 3 (2, 0 to 4) 5 (3, 0 to 6) 0.312
Moderate 24 (16, 10 to 22) 31 (20, 14 to 27) 14 (9, 5 to 14) 26 (16, 10 to 22) 0.058
All events 89 (58, 50 to 66) 93 (61, 53 to 69) 81 (53, 45 to 61) 88 (54, 46 to 61) 0.451
Skin‡:
Severe 1 (1, 0 to 2) 2 (1, 0 to 3) 3 (2, 0 to 4) 1 (1, 0 to 2) 0.635
Moderate 2 (1, 0 to 3) 12 (8, 4 to 12) 5 (3, 1 to 6) 4 (2, 0 to 5) 0.013
All events 36 (24, 17 to 30) 40 (26, 19 to 33) 36 (24, 17 to 30) 34 (21, 15 to 27) 0.730
Skin and vaginal§:
Severe 2 (1, 0 to 3) 2 (1, 0 to 3) 4 (3, 0 to 5) 1 (1, 0 to 2) 0.509
Moderate 5 (3, 1 to 6) 13 (9, 4 to 13) 9 (6, 2 to 10) 4 (2, 0 to 5) 0.058
All events 45 (29, 22 to 37) 45 (29, 22 to 37) 42 (28, 20 to 35) 40 (24, 18 to 31) 0.717
Other:
Severe 3 (2, 0 to 4) 5 (3, 0 to 6) 4 (3, 0 to 5) 2 (1, 0 to 3) 0.644
Moderate 12 (8, 4 to 12) 16 (11, 6 to 15) 12 (8, 4 to 12) 12 (7, 3 to 11) 0.748
All events 46 (30, 23 to 37) 47 (31, 23 to 38) 48 (31, 24 to 39) 36 (22, 16 to 28) 0.201
*Symptoms include headache, strange or vivid dreams, dizziness, anxiety, depression, sleeplessness, and visual disturbance.
†Nausea, diarrhoea, mouth ulcers.
‡Itching, abnormal reddening of skin.
§Itching, abnormal discharge.
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possibly because we used the monohydrate salt of
doxycycline and because participants were instructed
to take drugs with a glass of water after food and not
before bedtime. Skin reactions, including photosensi-
tivity, were expected. One third of the severe problems
with doxycycline were skin reactions, although the
highest proportions of all such reactions were in the
combined chloroquine and proguanil arm. Our
participants were advised to use sunscreens and were
warned that one of the study drugs was potentially
phototoxic. Regression analysis showed no increased
risk of vaginal candidiasis with doxycycline. This good
tolerability confirms the results of an uncontrolled,
questionnaire survey of Australian travellers.23
A recent meta-analysis evaluated the tolerability of
mefloquine in 2750 non-immune adults and found
that the incidence of adverse events was no greater
than that of any comparator regimen.24 Tolerability
studies have, however, repeatedly highlighted the
problem of neuropsychological problems with meflo-
quine. Several studies and a review have shown that
women are significantly more likely to experience
adverse events with mefloquine than with comparator
drugs.8 10 23 25 We found a significant excess of moderate
neuropsychological problems with mefloquine com-
pared with doxycycline and combined atovaquone and
proguanil but not with combined chloroquine and
proguanil. Furthermore, regression analysis between
the medication and sex showed that significantly more
women taking mefloquine reported mild to moderate
neuropsychological problems (including headache
and sleep disturbances) than those taking the other
drugs. This confirms the results of earlier uncontrolled
questionnaire studies.
Although studies have shown that combined
chloroquine and proguanil is associated with a high
incidence of adverse events, some health authorities
still recommend its use.7 8 26 We found the poorest
tolerability to this combination, but the drug remains
an alternative treatment when other drugs are
contraindicated.
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